NEXMED
Comparison · educational

Wegovy vs Mounjaro

A comparison of semaglutide (Wegovy) and tirzepatide (Mounjaro): estimated results, mechanism, dose schedule and side effects.

Weight-loss projection

Wegovy
−14.2 kg (~14.9%)
Mounjaro
−19.9 kg (~20.9%)

Average values from different clinical trials (STEP 1 vs SURMOUNT-1), not a head-to-head comparison. Individual results vary.

WegovyMounjaro
Active substancesemaglutidetirzepatide
Drug classGLP-1 agonistdual GIP/GLP-1 agonist
How it is givenweekly, subcutaneousweekly, subcutaneous
Maintenance dose2.4 mgup to 15 mg
Dose escalation16 weeksup to ~20 weeks
Average weight loss (trials)~14.9% (STEP 1, 68 weeks)~15–20.9% (SURMOUNT-1, 72 weeks)

Wegovy and Mounjaro at a glance

Wegovy (semaglutide) and Mounjaro (tirzepatide) are two once-weekly injectable medicines used for chronic weight management, and both are increasingly popular. Although the goal is similar (reducing appetite and losing weight), they differ in mechanism, in the size of the results seen in trials and in their dosing schedule. This page compares them point by point, based on public data from the prescribing information and clinical trials.

How each one works

The fundamental difference is the mechanism of action. Wegovy mimics a single gut hormone, while Mounjaro acts on two at once, which explains its larger average effects in trials.

  • Wegovy (semaglutide): GLP-1 receptor agonist. It reduces appetite, increases fullness and slows stomach emptying.
  • Mounjaro (tirzepatide): dual GIP + GLP-1 agonist. The same effects, amplified by its action on a second hormone receptor, with added benefits for blood sugar control.

Which one leads to more weight loss

Trial data point to an advantage for tirzepatide. The averages in the chart above come from different trials (STEP 1 for semaglutide, SURMOUNT-1 for tirzepatide), not from a direct comparison. In SURMOUNT-1, tirzepatide reached ~15% on 5 mg and up to ~20.9% on 15 mg (72 weeks), while semaglutide 2.4 mg showed ~14.9% in STEP 1 (68 weeks). Your own result depends on dose, diet, physical activity and adherence; use the chart above for a rough estimate.

Side effects: are they different?

The safety profile is similar. The most common effects are digestive (nausea, diarrhoea, constipation, bloating), usually mild and temporary, and more noticeable after each dose increase. Gradual dose escalation, smaller meals, good hydration and avoiding very fatty foods reduce these symptoms. Both also have contraindications (for example a history of medullary thyroid carcinoma or MEN2 syndrome, or pancreatitis), which your doctor will assess.

How they are given and dose escalation

Both are injected under the skin once a week, with the dose increased gradually. Wegovy reaches 2.4 mg over 16 weeks; Mounjaro starts at 2.5 mg and goes up in 2.5 mg steps at least every 4 weeks, to a maximum of 15 mg. Slow escalation is essential for tolerability: do not rush and do not skip steps.

Availability

Both are prescription-only medicines and should only be obtained through licensed pharmacies with a valid prescription. In the United States, tirzepatide for weight management is sold as Zepbound; in the EU and UK, Mounjaro is approved for both type 2 diabetes and weight management. Avoid unofficial sources: the risk of counterfeit products is real.

How to choose between Wegovy and Mounjaro

There is no universal answer. The decision is made with your doctor and takes several factors into account:

  • Your medical profile: in type 2 diabetes, tirzepatide (as Mounjaro) has a specific indication.
  • Your weight-loss goal and realistic expectations.
  • How well you tolerate digestive side effects, and your medical history.
  • Long-term access to treatment (it is meant to be taken long term).

Wegovy vs Mounjaro: frequently asked questions

Which causes more weight loss, Wegovy or Mounjaro?+

In separate trials, tirzepatide (Mounjaro) showed greater average weight loss (~15–20.9% at doses of 5–15 mg) than semaglutide 2.4 mg (Wegovy, ~14.9%). This is not a direct head-to-head comparison, and individual results vary considerably.

What is the difference in how Wegovy and Mounjaro work?+

Wegovy (semaglutide) is a GLP-1 receptor agonist, while Mounjaro (tirzepatide) is a dual GIP + GLP-1 agonist: it acts on two hormone receptors. The dual action of tirzepatide is associated, on average, with larger effects on weight and blood sugar.

Which has fewer side effects?+

Both have a similar side-effect profile, mainly digestive (nausea, diarrhoea, constipation), especially when the dose goes up. There is no clear difference in tolerability that applies to everyone: it depends on the individual.

Can you switch from Wegovy to Mounjaro (or the other way round)?+

Switching between the two should only be done on your doctor's advice; they will decide the right starting dose of the new medicine. Do not switch treatment on your own.

Can Wegovy and Mounjaro be taken together?+

No. Two medicines from this class are not used at the same time. Both are incretin receptor agonists, and combining them increases the risk of side effects with no proven benefit.

How long does it take to see results?+

The effect builds gradually: the first weeks are spent escalating the dose, and weight loss usually becomes noticeable after 1–2 months and continues over several months. See the timeline in each medicine's calculator.

What happens if I stop treatment?+

When treatment stops, some of the weight often comes back because appetite increases again. That is why both are used long term, combined with a balanced diet and physical activity.

How do I choose between Wegovy and Mounjaro?+

The choice depends on your medical profile (including type 2 diabetes, for which tirzepatide is indicated), tolerability, your goals and access to treatment, and is made together with your doctor. There is no universally "better" option.

Other calculators

The comparison uses average values from different clinical trials (STEP 1 vs SURMOUNT-1) and is for educational purposes only. It does not replace medical advice. Both are prescription medicines: the decision rests with your doctor.